Aripiprazole lauroxil (Aristada) vs Aripiprazole lauroxil (Aristada Initio)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline

Aripiprazole lauroxil (Aristada)

Marketed by Alkermes plc

Approved in Schizophreniasmall molecule
Reliable signal

NCT01469039 · Phase 3 · completed

The trial was randomized, quadruple-blinded, and placebo-controlled, with 623 participants assigned to aripiprazole lauroxil 441 mg, 882 mg, or placebo. Its primary clinical symptom endpoint, change in PANSS total score at day 85, was significantly better with both active doses than with placebo (p<0.001 for each comparison).

Reported efficacy

The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39) (met)

Result source: NCT01469039

Aripiprazole lauroxil (Aristada Initio)

Marketed by Alkermes plc

Approved in Schizophreniasmall molecule (long-acting injectable prodrug)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAripiprazole lauroxil (Aristada)Aripiprazole lauroxil (Aristada Initio)
PANSS total, change-21.8 vs -9.8−12 vs placebo882 mg · wk 12.14 · n 204NCT01469039
1 other result
  • -20.9 vs -9.8 441 mg · wk 12.14 · n 196 · Phase 3 · primary NCT01469039
—Not reported
CGI-S, change-0.5 vs -0.9+0.4 vs placebo441-441 mg · wk 52 · n 80NCT01626456
2 other results
  • -0.3 vs -0.9 882-882 mg · wk 52 · n 94 · Phase 3 · secondary NCT01626456
  • -0.2 vs -0.9 wk 52 · n 233 · Phase 3 · secondary NCT01626456
—Not reported
PANSS response—Not reported—Not reported
PSP, change—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

PANSS total, change

Aripiprazole lauroxil (Aristada)
-21.8 vs -9.8−12 vs placebo882 mg · wk 12.14 · n 204NCT01469039
1 other result
  • -20.9 vs -9.8 441 mg · wk 12.14 · n 196 · Phase 3 · primary NCT01469039
Aripiprazole lauroxil (Aristada Initio)
—Not reported

CGI-S, change

Aripiprazole lauroxil (Aristada)
-0.5 vs -0.9+0.4 vs placebo441-441 mg · wk 52 · n 80NCT01626456
2 other results
  • -0.3 vs -0.9 882-882 mg · wk 52 · n 94 · Phase 3 · secondary NCT01626456
  • -0.2 vs -0.9 wk 52 · n 233 · Phase 3 · secondary NCT01626456
Aripiprazole lauroxil (Aristada Initio)
—Not reported

PANSS response

Aripiprazole lauroxil (Aristada)
—Not reported
Aripiprazole lauroxil (Aristada Initio)
—Not reported

PSP, change

Aripiprazole lauroxil (Aristada)
—Not reported
Aripiprazole lauroxil (Aristada Initio)
—Not reported

Relapse (% of patients)

Aripiprazole lauroxil (Aristada)
—Not reported
Aripiprazole lauroxil (Aristada Initio)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Aripiprazole lauroxil (Aristada Initio): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Aripiprazole lauroxil (Aristada): 4 of 4 rows · Aripiprazole lauroxil (Aristada Initio): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAripiprazole lauroxil (Aristada)
Dropout rate
35.1%882 mga
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
37.2%441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.8%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.8%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.4%
NCT02634320 · Phase 4 · registry result, not featured evidence
12.4%High
NCT01895452 · Phase 3 · registry result, not featured evidence
6.2%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—882 mga
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
—441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
7.3%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
1.8%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.9%
NCT02634320 · Phase 4 · registry result, not featured evidence
1.8%High
NCT01895452 · Phase 3 · registry result, not featured evidence
1.5%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
Serious AEs
1.9%882 mga
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
1.4%441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
4.1%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
0%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.8%
NCT02634320 · Phase 4 · registry result, not featured evidence
1.8%High
NCT01895452 · Phase 3 · registry result, not featured evidence
0%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
882 mga
insomnia 12% (placebo 11.6%)
akathisia 11.1% (placebo 4.3%)
headache 8.7% (placebo 8.2%)
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
441 mg
akathisia 11.6% (placebo 4.3%)
insomnia 9.7% (placebo 11.6%)
headache 8.2% (placebo 8.2%)
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
insomnia 10.1%
weight increased 4.6%
headache 3%
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
headache 6.4%
weight increased 6.4%
insomnia 2.7%
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
anxiety 5.9%
NCT02634320 · Phase 4 · registry result, not featured evidence
High
insomnia 7.1%
nasopharyngitis 4%
diarrhoea 3.1%
NCT01895452 · Phase 3 · registry result, not featured evidence
Low
diarrhoea 6.2%
nasopharyngitis 6.2%
toothache 6.2%
NCT01895452 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aripiprazole lauroxil (Aristada)

PANSS Total -21.8 vs -9.8 placebo score @ 12.14wk882 mg
absolute change · score
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 1 more result
-20.9 vs -9.8 placebo score @ 12.14wk441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S -0.5 vs -0.9 placebo score @ 52wk441-441 mg
absolute change · score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-0.3 vs -0.9 placebo score @ 52wk882-882 mg
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.2 vs -0.9 placebo score @ 52wk
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Total -10 vs -19.1 placebo score @ 52wk441-441 mg
absolute change · score
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-8.3 vs -19.1 placebo score @ 52wk882-882 mg
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-5.9 vs -19.1 placebo score @ 52wk
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Positive Subscale -3.4 vs -5.8 placebo score @ 52wk441-441 mg
absolute change · score
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-2.3 vs -5.8 placebo score @ 52wk882-882 mg
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.8 vs -5.8 placebo score @ 52wk
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Negative Subscale -1.5 vs -4.1 placebo score @ 52wk441-441 mg
absolute change · score
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-2.1 vs -4.1 placebo score @ 52wk882-882 mg
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.2 vs -4.1 placebo score @ 52wk
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS General Psychopathology -5.1 vs -9.2 placebo score @ 52wk441-441 mg
absolute change · score
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-4 vs -9.2 placebo score @ 52wk882-882 mg
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-2.9 vs -9.2 placebo score @ 52wk
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S -0.2 score
absolute change · score
No placebo or comparator arm
NCT02634320 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.1 scoreLow
NCT01895452 · Phase 3 · registry result, not featured evidence
-0.1 scoreHigh
NCT01895452 · Phase 3 · registry result, not featured evidence
BPRS Total -2.7 score
absolute change · score
No placebo or comparator arm
NCT02634320 · Phase 4 · registry result, not featured evidence
QLS Total 0.4 score
absolute change · score
No placebo or comparator arm
NCT02634320 · Phase 4 · registry result, not featured evidence
PANSS Total -0.7 scoreLow
absolute change · score
No placebo or comparator arm
NCT01895452 · Phase 3 · registry result, not featured evidence
show 1 more result
-0.9 scoreHigh
NCT01895452 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole lauroxil (Aristada)'s landscape · Aripiprazole lauroxil (Aristada Initio)'s landscape